Psoriasis News and Research

Latest Psoriasis News and Research

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

News outlets report on the creative outreach efforts, including those geared to moms, young people and Latinos, to increase the number of newly insured people before March 31. Even prison inmates are signing up.

11 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

The incidence of autism spectrum disorders has increased sharply since it was first described 60 years ago. Today, ASD affects more than 1% of all children in the U.S. and about half of them develop a life-long disability.

3 Mar 2014

Researchers discover novel treatments for psoriasis that are likely to cause fewer side effects

Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.

28 Feb 2014

Waiting room time helps in effective screening for depression and anxiety

A new study in General Hospital Psychiatry finds patients visiting the hospital for a variety of ailments can be easily screened for depression and anxiety as they wait for care, information that can then be sent immediately to their doctor to address.

27 Feb 2014

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Researchers have long known that people with autoimmune diseases, such as hepatitis, type 1 diabetes, multiple sclerosis and psoriasis, are at greater risk of developing schizophrenia.

24 Feb 2014

Research sheds light on pathological mechanisms that trigger psoriasis lesions

Streptococcal antigens (Streptococcus pyogenes) might be directly involved in the pathological mechanisms that result in the appearance of psoriasis lesions.

21 Feb 2014

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.

20 Feb 2014

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.

18 Feb 2014

New research identifies raised risk of self-harm among patients with certain physical illnesses

New research quantifying the risk of admission to hospital for self-harm has identified a raised risk of self-harm among groups of patients with certain physical illnesses. While it is known that psychiatric illnesses are associated with a greatly elevated risk of self-harm, a moderately elevated risk was seen with common physical illnesses such as diabetes, epilepsy and asthma.

13 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Researchers identify effective target for human autoimmune disease

Researchers at King's College London have identified a new gene (PIM1), which could be an effective target for innovative treatments and therapies for the human autoimmune disease, psoriasis.

13 Feb 2014

Loyola pediatric dermatologists now offer same-day appointments to see kids

The next time your baby develops a rash or your teen has a severe acne outbreak, help is just a quick appointment away. Loyola University Health System pediatric dermatologists now offer same-day or next-day appointments to see your child.

11 Feb 2014

Nestlé focuses on meeting world's increasing skin health needs

Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world's increasing skin health needs with a scientifically-proven broad range of innovative products.

11 Feb 2014

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

Psoriasis is the most common autoimmune disease in the US, affecting 2 to 3% of all Americans. What causes psoriasis in any one individual will stem from a mixture of their genetic background and their environment.

4 Feb 2014

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

28 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

The National Institutes of Health has awarded Benaroya Research Institute at Virginia Mason a 7-year grant to lead the Immune Tolerance Network.

24 Jan 2014

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

To advance understanding of psoriasis—the most common autoimmune disease in the country, affecting up to 7.5 million Americans—and help scientists and clinicians improve treatments and patient outcomes, the National Psoriasis Foundation and the Consortium of Rheumatology Researchers of North America, Inc. will create the first psoriasis registry co-developed and co-administered by a nonprofit.

10 Jan 2014

Psoriasis News and Research

Latest Psoriasis News and Research

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

Antares Pharma announces launch of OTREXUP to Dermatologists

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

Researchers discover novel treatments for psoriasis that are likely to cause fewer side effects

Waiting room time helps in effective screening for depression and anxiety

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Research sheds light on pathological mechanisms that trigger psoriasis lesions

XenoPort reports net loss of $19.1 million for fourth quarter 2013

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

New research identifies raised risk of self-harm among patients with certain physical illnesses

Alvogen launches Inflectra into Central and Eastern Europe

Researchers identify effective target for human autoimmune disease

Loyola pediatric dermatologists now offer same-day appointments to see kids

Nestlé focuses on meeting world's increasing skin health needs

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Psoriasis News and Research

Latest Psoriasis News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in